25.15 — Generics, Biosimilars, Patents and Exclusivity

Atorvastatin, sold as Lipitor, was for years the best-selling medicine in the world, earning around thirteen billion dollars a year. Its American patent protection ended in November 2011.

Within a year, the price had collapsed by more than ninety percent and the brand had lost most of its volume. Nothing about the molecule changed. Nothing about its effectiveness changed. A legal date passed.

That moment — the industry calls it the patent cliff — is the single most important economic event in the life of a medicine, and everything in this chapter is either about delaying it, surviving it, or exploiting it.

Why generics need a special pathway at all

Consider the problem from 1983. A company wants to sell a copy of a drug whose patent has expired. Under the law as it then stood, it had to file its own full application, with its own clinical trials proving safety and effectiveness — for a molecule already proven, in patients who would receive a treatment already known to work.

That is unaffordable and unethical at the same time: unaffordable because the copy would have to be priced like the original, and unethical because giving patients placebo to re-prove a settled question wastes people.

The Hatch–Waxman Act of 1984 solved it with a trade. Generic companies got a short application route — the abbreviated new drug application, the ANDA — requiring no new clinical trials, only proof that the copy is the same drug and behaves the same in the body. Brand companies got compensations: extra time added back to patents to make up for years lost during review, and a period of protection during which no generic could rely on their data.

Roughly nine out of ten prescriptions in the United States are now filled with generics, while most of the money still goes to brands. That single sentence describes the bargain working exactly as designed.

What a generic must prove: bioequivalence

A generic must contain the same active ingredient, in the same strength, in the same dosage form, for the same use, given by the same route. The inactive ingredients may differ. What must be proved is bioequivalence.

The study is simple to describe. Usually twenty-four to thirty-six healthy volunteers take the generic on one occasion and the brand on another, in random order with a washout period between. Blood samples are taken over time, and two measurements are compared: the total exposure, the area under the concentration-time curve, and the peak concentration reached.

The acceptance criterion is where people misunderstand the standard, so it is worth stating precisely. The 90 percent confidence interval for the ratio of generic to brand, for both measurements, must lie entirely between 80 and 125 percent.

Two points follow, and the second is the one almost everyone gets wrong.

The limits are not symmetrical because the comparison is a ratio. One divided by 1.25 is 0.8, so 80 and 125 percent are equally distant in the way ratios actually behave.

And the requirement is not that the average may differ by up to 25 percent. It is that the entire confidence interval must sit inside the window, which in practice forces the observed average difference to be small — typically a few percent — because a study with any real variability could not otherwise fit inside the boundaries. The common complaint that "generics are allowed to be 20 percent off" is a misreading of the statistics, and being able to explain why is genuinely useful.

Some products need more. Narrow therapeutic index drugs, where the gap between an effective and a toxic dose is small, face tighter limits. Locally acting products — an inhaler, a cream — cannot be assessed by blood levels at all, and need comparative clinical or specialised studies, which is why generic versions of some inhalers took decades to appear.

The patent and exclusivity machinery

Two separate systems protect a brand, and confusing them is the most common error in this area.

Patents are granted by the patent office and cover an invention. Exclusivity is granted by the drug regulator and blocks approval of a competitor for a period. They run independently, and either can be the binding constraint.

Patents on a medicine come in layers. The compound patent covers the molecule itself and is the strongest. Then patents on formulations, manufacturing processes, crystal forms, combinations, and methods of use for a specific disease. A twenty-year term runs from filing, and since filing happens early in development, the effective commercial life after approval is often only ten to fourteen years — which is the reason the Hatch–Waxman restoration of lost time exists.

The exclusivities in the United States are worth knowing by their durations, because clients plan around them.

Exclusivity	Length
New chemical entity	5 years
New clinical study on an approved drug	3 years
Orphan drug designation	7 years
Paediatric studies, added on	6 months
First generic to challenge a patent	180 days
New biological product	12 years

The paediatric extension deserves a note because it is unusually effective policy. A company that completes studies in children requested by the agency receives six extra months added to its existing exclusivities and patents. On a drug earning billions a year, six months is worth far more than the studies cost, which is precisely why children's dosing information now exists for a great many drugs where it previously did not.

The patent fight, and how it is choreographed

Hatch–Waxman built a structured way for a generic company to challenge a brand's patents rather than simply waiting them out.

Brand patents are listed in a public register the industry calls the Orange Book. When a generic company files, it must certify against each listed patent — that the patent has expired, that it will wait for expiry, or, in the aggressive case, that the patent is invalid or not infringed by its product. That last one is the famous Paragraph IV certification.

Filing it starts a clock. The brand company is notified and normally sues. If it sues within 45 days, approval of the generic is automatically stayed for up to 30 months while the case proceeds, unless the court decides sooner.

And the incentive that makes generic companies take the risk is the 180-day exclusivity: the first filer to challenge successfully gets six months during which it is the only generic on the market. With only one competitor, prices fall modestly; once several generics enter, prices fall steeply — commonly to a small fraction of the brand price. So the first-filer's six months can be worth more than the following decade.

Biosimilars: why copying a biologic is different

Everything above assumes the copy can be identical. For a biologic made in living cells, it cannot be, for the reasons in Chapter 25.11 — the process is the product, and no company can obtain another's cell line, media and purification steps.

So the law created a different category. A biosimilar is a biological product highly similar to an approved reference product, with no clinically meaningful differences in safety, purity and potency. In the United States this pathway came from the Biologics Price Competition and Innovation Act of 2010, and applications are filed under section 351(k).

The evidence required is shaped like a pyramid standing on its head, which is the opposite of a new drug's.

The base is extensive analytical comparison — dozens of methods comparing structure, sugar attachments, charge variants, aggregation, and biological activity against many batches of the reference product. This is where most of the evidence sits, because analytical methods can now detect differences far smaller than any clinical study could.

Then functional and animal studies where needed, then human pharmacokinetic comparison, and finally a comparative clinical study only if uncertainty remains. The trend has been to require less clinical work as analytical science improves, and in recent years regulators have moved further in that direction.

Two extra concepts appear only in the biologics world.

Interchangeability. In the United States, a biosimilar can be designated interchangeable, which allows a pharmacist to substitute it without the prescriber's involvement, subject to state law. This required additional evidence, historically including switching studies, and the requirements have been loosened as experience accumulated. Europe never created this distinction; substitution there is handled at national level.

And the disclosure process the industry nicknamed the patent dance — a defined sequence of information exchanges between the biosimilar applicant and the reference company about which patents are at issue, running before litigation. The reference product's patents are published in the register known as the Purple Book, the biologics counterpart of the Orange Book.

Biosimilars have delivered savings, but far less dramatically than generics. Development costs tens to hundreds of millions rather than a few million, manufacturing is capital-intensive, and price reductions are typically in the range of tens of percent rather than ninety. That difference in economics is why a biologic losing protection is a much softer cliff than a small molecule losing it.

How companies defend against the cliff

Some tactics are legitimate product development and some are widely criticised. Knowing which is which lets you follow the argument when a client's strategy team is talking.

Genuine lifecycle work: a new formulation that is taken once a day instead of three times, a new delivery device, a paediatric formulation, approval in an additional disease, or a fixed-dose combination that genuinely simplifies treatment.

Contested tactics: filing large numbers of secondary patents around an ageing product to extend the total protected period, switching patients to a slightly modified version shortly before the original loses protection, paying a generic challenger to delay entry, and citing safety requirements to restrict a competitor's access to samples needed for bioequivalence testing.

And one manoeuvre worth understanding because it looks strange from outside. A brand company can launch its own generic, called an authorised generic, through a subsidiary — the identical product without the brand name, sold at a generic price, timed to compete with the first challenger during their exclusivity period.

The honest summary is that this area is a permanent tension between two things society wants: rewards large enough to fund the 93 percent of programmes that fail, and cheap medicines as soon as the reward period ends. There is no arrangement that fully satisfies both, and every country has settled it slightly differently.

Outside the United States, in one paragraph

Europe uses a different structure with the same intent. A new medicine gets eight years of data protection, during which no generic may rely on the originator's data, plus two further years of market protection, plus one more year if a significant new use is approved during the first eight — the arrangement everyone shortens to "eight plus two plus one". Supplementary protection certificates extend patent life to compensate for development time, in the same spirit as the American restoration.

India's system, historically built around process patents rather than product patents, is a large part of why the country became the world's principal supplier of affordable generics, and its patent law includes a provision limiting patents on modified versions of known substances without a significant improvement in efficacy.

Where the systems work is

Three practical areas generate steady project work here.

Intellectual property and exclusivity tracking — a database of every patent, every filing, every certification, every exclusivity and every expiry, across every market, feeding the forecasting that decides where a company invests.

Generic and biosimilar manufacturers' own regulatory operations — high-volume, low-margin, submission-heavy work, where automation of dossier preparation directly improves the business.

And formulary and pricing analytics on the payer side, where the arrival of a generic changes what a health plan is willing to cover, described in Chapters 25.27 and 25.29.

Next: Chapter 25.16, the device rulebook — a completely different regulatory system for products that work by physics rather than chemistry, and the one your software is most likely to fall inside.